Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data that further define the genomic landscape around thyroid cancer. The study findings help characterize the role of specific gene alterations known as variants and fusions in predicting thyroid cancer and also reinforce the potential for Veracyte’s Afirma® Xpression Atlas (XA) genomic test to help guide personalized surgery and treatment decisions for patients with suspected or confirmed thyroid cancer. The new study appears online in the journal Thyroid.For the new analysis, researchers evaluated data from 61 published studies involving 4,648 thyroid nodule samples to determine the frequency of specific variants and fusions and the likelihood of cancer when they are detected in preoperative patient samples. The study focused on thyroid nodule samples that were
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Morgan Stanley from $26.00 to $28.00. They now have an "underweight" rating on the stock.MarketBeat
- Veracyte, Inc. (NASDAQ: VCYT) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
- Veracyte, Inc. Just Recorded A 296% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
- Veracyte, Inc. (NASDAQ: VCYT) had its price target raised by analysts at Scotiabank from $40.00 to $44.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Veracyte Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 11/6/24 - Beat
VCYT
Sec Filings
- 11/21/24 - Form 4
- 11/19/24 - Form 144
- 11/14/24 - Form 4
- VCYT's page on the SEC website